- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04323046
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To measure the relative changes in cell cycle-related genetic signature of the tumor microenvironment post administration of neoadjuvant nivolumab in children and young adults with recurrent or progressive HGG when compared to a cohort of archived non-treated recurrent pediatric HGG samples.
II. To characterize the safety and tolerability of neoadjuvant nivolumab followed by adjuvant nivolumab in children and young adults with recurrent or progressive HGG.
SECONDARY OBJECTIVES:
I. To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
II. To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
EXPLORATORY OBJECTIVES:
I. To measure relative changes in interferon gamma associated genetic signature within the tumor microenvironment post administration of neoadjuvant nivolumab in children and young adults with recurrent or progressive HGG compared to archived non-treated recurrent pediatric HGG samples.
II. To explore the correlation of interferon-gamma-associated genetic signature, cell cycle-related genetic signature and infiltrating T lymphocyte (TIL) density and clonality with clinical responses.
III. To measure TIL density post administration of neoadjuvant nivolumab in children and young adults with recurrent or progressive HGG.
IV. To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
V. To evaluate the association between advanced MRI parameters (ADC on DWI, rCBV on dynamic susceptibility contrast (DSC) perfusion MRI, pre-contrast T1 shortening on T1-weighed images, and/or MTRasym on pH-Weighted Amine CEST-EPI) and tumor and peripheral blood immune responses.
VI. To measure relative change in peripheral T-cell response and post administration of neo-adjuvant nivolumab in children and young adults with recurrent or progressive HGG.
VII. To measure PD-1 and PDL-1 expression by immunohistochemistry for children and young adults with recurrent or progressive HGG post neoadjuvant nivolumab and evaluate the differences between the treatment cohort and archived non-treated recurrent pediatric HGG samples.
VIII. To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
IX. To assess Quality of Life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab followed by adjuvant nivolumab.
X. To assess patient and/or proxy satisfaction with study participation via patient-reported outcome (PRO) measures in the context of race ethnicity and other health related social risks.
XI. To assess on therapy toxicity in the context of race, ethnicity and other health related social risks.
OUTLINE: Neoadjuvant nivolumab followed by adjuvant nivolumab evaluation.
NEOADJUVANT TREATMENT: Participants will receive a single infusion of nivolumab of 3 mg/kg 14± 5 days prior to surgery. When scheduling, please keep in mind that the two pre-surgical plasma samples (day of neoadjuvant dose and day of surgery) should be drawn greater than 10 days apart.
Tumor samples will be obtained at time of surgery. The tissue from this surgery (fresh, frozen and FFPE) and the archived tissue (FFPE) from the most recent surgery prior to registration revealing HGG will be processed so as to best achieve the primary, secondary and exploratory objectives.
ADJUVANT TREATMENT: Infusion Cycle #1 should begin as soon as participant has recovered from surgery and has been tapered off of steroids. A maximum dexamethasone dose of 0.1 mg/kg/day is allowed, but preferably have been discontinued (inhaled or topical use of steroids is allowed).
Maintenance Cycle 1+ Day 1 & 15: Participants will receive nivolumab (3mg/kg) IV every 2 weeks until progression or development of unacceptable toxicities or withdrawal. Blood samples will be obtained as pharmacodynamic markers throughout the study (Day 1 of every other cycle). Dose interruptions and symptomatic management will occur based upon preset adverse event determination.
After completion of study treatment, patients are followed up at 30 days and then every 2 months for up to 5 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jannerfer An
- Phone Number: (415) 476-3831
- Email: PNOC019@ucsf.edu
Study Contact Backup
- Name: Sabine Mueller, MD, PhD
- Phone Number: (415) 476-3831
- Email: PNOC019@ucsf.edu
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 1291
- Recruiting
- Sydney Children's Hospital
-
Contact:
- David Ziegler, BSc (Med), MBBS, FRACP, MD/PhD
- Phone Number: 61 2 9382 1111
- Email: d.ziegler@unsw.edu.au
-
Westmead, New South Wales, Australia, 2152
- Recruiting
- The Children's Hospital at Westmead
-
Contact:
- Regienald Gayaman
- Phone Number: +61 2 9845 0925
- Email: regienald.gayaman@health.nsw.gov.au
-
Principal Investigator:
- Dinisha Govender, MBChB, FRACP
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Recruiting
- Queensland Children's Hospital
-
Contact:
- Natasha Brown
- Phone Number: +61 7 3069 7206
- Email: natasha.brown@health.qld.gov.au
-
Contact:
- Karen Clements
- Phone Number: +61 7 3069 7441
- Email: karen.clements@health.qld.gov.au
-
Principal Investigator:
- Tim Hassall, MBBS, FRACP
-
-
South Australia
-
North Adelaide, South Australia, Australia, 5006
- Recruiting
- Women's and Children's Hospital
-
Contact:
- Callie Ayles
- Phone Number: (08) 81619162
- Email: callie.ayles@sa.gov.au
-
Contact:
- James Kirby
- Phone Number: +61 8 8161 8922
- Email: James.Kirby@sa.gov.au
-
Principal Investigator:
- Maria Kirby, MBBS FRACP
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Recruiting
- Royal Children's Hospital
-
Contact:
- Yun Y Tu
- Phone Number: +61 3 9345 9184
- Email: yunyan.tu@mcri.edu.au
-
Principal Investigator:
- Kanika Bhatia, MD
-
-
Western Australia
-
Perth, Western Australia, Australia, 6009
- Recruiting
- Perth Children's' Hospital
-
Contact:
- Nick Gottardo, MB,ChB,FRACP,PhD
- Email: Nick.Gottardo@health.wa.gov.au
-
-
-
-
-
Ramat Gan, Israel
- Recruiting
- Sheba Medical Center
-
Contact:
- Michal Yalon
- Email: michal@droren.co.il
-
-
-
-
-
Zurich, Switzerland
- Recruiting
- The University Children's Hospital in Zurich
-
Contact:
- Nicolas Gerber, MD
- Email: nicolas.gerber@kispi.uzh.ch
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham, Children's of Alabama
-
Contact:
- Girish Dhall, MD
- Phone Number: 205-638-9285
- Email: gdhall@peds.uab.edu
-
Contact:
- Katie Metrock, MD
- Email: kmetrock@peds.uab.edu
-
-
California
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hospital of Los Angeles
-
Contact:
- Tom Davidson, MD
- Phone Number: 323-361-8147
- Email: tdavidson@chla.usc.edu
-
San Diego, California, United States, 92123
- Recruiting
- Rady Children's Hospital
-
Contact:
- Megan Paul, MD
- Email: mrpaul@rchsd.org
-
San Francisco, California, United States, 94115
- Recruiting
- University of California, San Francisco
-
Principal Investigator:
- Sabine Mueller, MD
-
Contact:
- Sabine Mueller, MD, Phd
- Email: Sabine.Mueller@ucsf.edu
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20310
- Recruiting
- Children's National Hospital
-
Contact:
- Lindsay Kilburn, MD
- Phone Number: 202-476-5973
- Email: lkilburn@cnmc.org
-
-
Florida
-
Gainesville, Florida, United States, 32611
- Recruiting
- University of Florida
-
Contact:
- Elias Sayour, MD, PhD
- Phone Number: 352-294-8347
- Email: Elias.Sayour@neurosurgery.ufl.edu
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Riley Children's Hospital
-
Contact:
- Scott Coven, DO, MPH
- Phone Number: 317-944-8784
- Email: scoven@iu.edu
-
Principal Investigator:
- Scott Coven, DO, MPH
-
Sub-Investigator:
- Runco Daniel, MD, MS
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins University
-
Contact:
- Kenneth Cohen, MD, MBA
- Phone Number: 410-614-5055
- Email: kcohen@jhmi.edu
-
Contact:
- Eric Raabe, MD
- Email: eraabe2@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana Farber Cancer Institute
-
Contact:
- Susan Chi, MD
- Phone Number: 617-632-2291
- Email: susan_chi@dfci.harvard.edu
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University St. Louis
-
Contact:
- Mohamed Abdelbaki, MD
- Phone Number: 314-286-2790
- Email: MohamedA@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack Meridian Children's Health at Joseph M. Sanzari Children's Hospital
-
Contact:
- Derek Hanson, MD
- Phone Number: 551-996-5437
- Email: derek.hanson@hmhn.org
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Doernbecher Children's Hospital Oregon Health & Science University
-
Contact:
- Linda Stork, MD
- Phone Number: 503-494-1543
- Email: storkl@ohsu.edu
-
Contact:
- Matthew Miller, MD
- Email: milmatth@ohsu.edu
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Recruiting
- University of Utah
-
Contact:
- Nicholas Whipple, MD
- Email: nicholas.whipple@hsc.utah.edu
-
Contact:
- Priya Chan
- Email: priya.chan@hsc.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants with recurrent or progressive high-grade gliomas (HGG) (World Health Organization (WHO) grade III or grade IV) who are candidates for surgical tumor debulking will be enrolled in this trial
- All assessments are to occur within 14 days of registration except where otherwise noted. The participant and their legal parent/guardian must be thoroughly informed about all aspects of the study, including the study visit schedule and required evaluations and all regulatory requirements for informed consent. The written informed consent must be obtained from the participant and legal parent/guardian prior to enrollment
- Have a history of previously treated histologically confirmed World Health Organization grade III or IV HGG. Previous first line therapy with radiation and/or chemotherapy
- Have evidence of recurrence or progression of disease by MRI scan
- Participants must be adequate medical candidates for surgical resection. The intent of surgical resection is to allow both cytoreduction and tumor debulking as part of standard of care, and also collect a minimum of 100 mg of tumor tissue for the study tissue endpoints
- A primary goal of surgery must be cytoreduction, and not solely on diagnostic biopsy
- Age: Participants must be > 6 months and < 25 years of age at time of enrollment
- Karnofsky >= 50 for participants > 16 years of age and Lansky >= 50 for participants =< 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment (on stable or tapering dosing of steroids). A baseline detailed neurological exam should clearly document the neurologic status of the patient at the time of enrollment on the study.
Prior Therapy: Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. At least 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
- An interval of at least 12 weeks from the completion of radiation therapy to registration unless there is unequivocal histologic confirmation of tumor progression
Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events (AEs) are known to occur. The duration of this interval must be discussed with the study chair.
- Had their last dose of biologic (anti-neoplastic agent) ≥7 days prior to study registration, or beyond the time during which AEs are known to occur.
- Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): At least 7 days after the last dose of agent
- Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
- An interval of at least 12 weeks from prior exposure to PD-1 or PD-L1 inhibitors.
Stem cell infusion (with or without total-body irradiation (TBI)):
- Autologous stem cell infusion including boost infusion: >= 42 days
- Participants must be willing to forego cytotoxic anti-tumor therapies except study-defined therapy while being treated on study
Organ Function Requirements:
- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
- Platelet count >= 100,000/mm^3
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:
- Age: Maximum Serum Creatinine (mg/dL)
- 6 months to < 3 years: 0.6 (male and female)
- 3 to < 6 years: 0.8 (male and female)
- 6 to < 10 years: 1 (male and female)
- 10 to < 13 years: 1.2 (male and female)
- 13 to < 16 years: 1.5 (male), 1.4 (female)
- >= 16 years: 1.7 (male), 1.4 (female)
- Bilirubin (sum of conjugated and unconjugated) =< 1.5 x upper limit of normal (ULN) for age (except participants with Gilbert syndrome who must have a total bilirubin level of < 3.0
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN
- Serum albumin >= 2
- Pregnancy: The effects of nivolumab on the developing human fetus are unknown. For this reason women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 5 months after completion of therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- MRI within 28 days prior to registration.
Exclusion Criteria:
- Current or planned participation in a study of an investigational agent or using an investigational device.
- Has a diagnosis of immunodeficiency.
- Has tumor primarily localized to the brainstem or spinal cord.
- Has presence of diffuse leptomeningeal disease or or disseminated/multi-focal disease, or extracranial disease.
- Has received systemic immunosuppressive treatments (such as methotrexate, chloroquine, azathioprine, etc.), aside from anti-neoplastic chemotherapy or systemic corticosteroids within six months of registration.
- Participants with a concurrent condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- Unable to taper steroids due to ongoing mass effect; a maximum dexamethasone dose of 0.1 mg/kg/day is allowed (4mg maximum), but preferably have been discontinued (inhaled or topical use of steroids is allowed).
- Has a known history of active TB (Bacillus tuberculosis).
- Has a known additional malignancy that is progressing or requires active treatment within 3 years of registration. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Has known history of, or any evidence of active non-infectious pneumonitis.
- Has an active infection requiring systemic therapy.
- Has a known hypersensitivity to any of the study therapy products.
Has a known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- NOTE: Testing for HIV must be performed at sites where mandated locally
- Any prior positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus, e.g., hepatitis B surface antigen (HBsAg, Australia antigen) positive, or hepatitis C antibody (anti-HCV) positive (except if HCV-ribonucleic acid (RNA) negative).
- Participants who have had prior allogenic hematopoietic stem cell transplant (HSCT).
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy or interfere with interpretation of study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neoadjuvant nivolumab and adjuvant nivolumab
NEOADJUVANT: Patients receive nivolumab IV over 30 minutes 14 days before undergoing standard of care surgical resection. ADJUVANT MAINTENANCE: After completion of neoadjuvant infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given IV
Other Names:
Ancillary studies, given in person or online
Other Names:
Ancillary studies, given in person or online
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with treatment-related adverse events
Time Frame: Up to 2 years
|
Adverse events will be monitored throughout the trial and graded in severity according to the guidelines outlined in the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 from initiation of study treatment until 2 years after treatment discontinuation or until study treatment related adverse events resolve or return to baseline, Adverse experiences (specific terms as well as system organ class terms) and predefined limits of change in laboratory, and vital sign parameters that are not pre-specified as events of interest will be summarized with descriptive statistics (counts, percentage, mean, standard deviation, etc.).
|
Up to 2 years
|
Percentage change in cell cycle-related genetic signature
Time Frame: From screening to surgery visit (neoadjuvant treatment groups); at time of recurrent high grade glioma (HGG) tissue collection (for archived non-treated samples)
|
Will assess the percentage change in cell cycle-related genetic signature post administration of neoadjuvant treatments when compared to archived recurrent pediatric HGG group.
The number of participants with high cell cycle gene signature (positive median gene set variation analysis (GSVA) score) will be tabulated.
Variables involved in the primary analyses will be examined graphically and summarized by descriptive statistics.
|
From screening to surgery visit (neoadjuvant treatment groups); at time of recurrent high grade glioma (HGG) tissue collection (for archived non-treated samples)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Up to 12 months
|
Survival will be assessed at 6 months and 12 months from the time of enrollment until the time of death.
Kaplan-Meier survival analyses will be performed.
Medians together with 2-sided 95% confidence intervals will be computed using a log-log transformation.
|
Up to 12 months
|
Progression-free survival (PFS)
Time Frame: Up to 12 months
|
PFS is defined as the time of enrollment until the time of progressive disease or death.
Kaplan-Meier survival analyses will be performed.
Medians together with 2-sided 95% confidence intervals will be computed using a log-log transformation.
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Tom Davidson (tdavidson@chla.usc.edu), MD, Children's Hospital Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Recurrence
- Glioma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- 190815
- NCI-2020-01502 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- PNOC 0019 (Other Identifier: University of California, San Francisco)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingRelapsing/Refractory ALK+ Anaplastic Large Cell LymphomaFrance, Denmark, Netherlands
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom